Quantcast

FDA prioritizes Dupinex for review

The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the @Regeneron Pharmaceuticals and Sanofi made supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable.

Read more

Quicker pathway to a pivotal trial for larger patient population than planned for Actinium’s CD33

@ActiniumPharma moves to next stage of development for its CD33 ARC (Antibody Radiation Conjugate) Ac-225-Lintuzumab program are pivotal trial pathway for its Actimab-MDS program for Myelodysplastic Syndromes (MDS), and also in two combination trials with Venetoclax for AML.
$ATNM

Read more

Plasticell bags €3.7 million EU funds for advancing neurodegenerative disease research

Advanced Stem Cell Training Network (ASCTN), a European research consortium , has successfully bid for over €3,700,000 in funding from the European Union to create and exploit advanced cellular models of neurological disorders – notably Parkinson´s, Huntington´s and Demyelination disease – which are caused by acute or progressive loss of cells in the brain, said Plasticell Ltd, a developer of stem cell technologies and regenerative medicines, in which the company is a partner organisation

Read more